HappyTidesHappyTidesAdvanced Peptides
Shop now

Learn · Topic guide

Peptide Nomenclature & Acronyms

Read a few peptide reference catalogues side by side and a pattern emerges: the names are not arbitrary. A string like "CJC-1295 with DAC" or "Mod GRF 1-29" encodes the parent hormone, the fragment boundaries, the engineered substitutions, and the half-life strategy all at once. Once the grammar is legible, a name becomes a compact spec sheet. This reference is written for laboratory and research-catalogue contexts only. Every statement here concerns molecular identity, sequence notation, and receptor-signaling classification observed in vitro or in cell and tissue models. Nothing here addresses use in people. We walk through how research peptides are named, why the same molecule can carry three or four labels, and what the recurring acronyms mean, then close with a glossary keyed to entries in the reference dataset. Where a specific peptide is cited, the facts come from that dataset's recorded sequence, formula, and mechanism fields. General naming principles are flagged as conventions of peptide chemistry rather than claims about any one compound.

Research use onlyStart reading ↓

Section 01

How peptides get their names: codes, fragments, and parent hormones

A research peptide usually carries several names at once, and each follows a different logic.

A research peptide usually carries several names at once, and each follows a different logic. Development codes are alphanumeric labels assigned by the originating laboratory: retatrutide was tracked as LY3437943 before it had a generic name, and tesamorelin carried the code TH9507 (TH-9507) during development. Generic names ending in stems like -relin (sermorelin, tesamorelin) flag a releasing-hormone analog class, while -tide (semaglutide, retatrutide, bremelanotide) marks a peptide drug. Fragment names cite the parent hormone plus a residue range: sermorelin is the 1-29 fragment of human GHRH and, per the dataset, is the shortest fragment retaining full GHRH activity at the receptor; tesamorelin retains the full native GHRH(1-44) backbone. TB-500 is named as a thymosin beta-4 fragment corresponding to residues 17-23. The numbering after a hormone abbreviation is therefore a map of which stretch of the parent sequence was synthesized. KPV (alpha-MSH 11-13) and Semax (built on ACTH(4-7) plus a Pro-Gly-Pro tail) follow the same fragment-of-a-hormone convention, with the residue indices doing the bookkeeping.

Section 02

DAC and GRF: two naming systems worth decoding

Two label families appear repeatedly in growth-hormone-axis research peptides and confuse newcomers most.

Two label families appear repeatedly in growth-hormone-axis research peptides and confuse newcomers most. GRF (growth hormone-releasing factor) is an older synonym for GHRH (growth hormone-releasing hormone); both name the same parent hormone and the same receptor target, GHRHR, a class B Gs-coupled GPCR on pituitary somatotrophs. So GRF(1-29) and GHRH(1-29) describe the same backbone. "Mod GRF 1-29" signals a modified version of that 29-residue fragment: in the dataset, CJC-1295 without DAC is exactly this, an amide of GHRH(1-29) carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27) at metabolically labile sites, with D-Ala2 conferring DPP-IV resistance. DAC stands for Drug Affinity Complex, an albumin-binding strategy. The dataset records CJC-1295 with DAC as the same substituted backbone plus a C-terminal Lys30 bearing an N-epsilon-maleimidopropionyl linker; that maleimide reacts with the free thiol of cysteine-34 on serum albumin to form a stable 1:1 thioether bioconjugate. The naming pair "with DAC / without DAC" therefore distinguishes two molecules: one carries the albumin-tethering extension, one does not.

Section 03

Sequence notation: one-letter, three-letter, and what the symbols mean

Peptide entries list sequences in two parallel notations.

Peptide entries list sequences in two parallel notations. Three-letter codes spell each residue (Gly-Glu-Pro for the start of BPC-157); the one-letter code compresses the same chain (GEPPPGKPADDAGLV). Both are read N-terminus to C-terminus. Several modifiers recur. A leading "Ac-" marks N-terminal acetylation, as in TB-500's Ac-LKKTETQ. A trailing "-NH2" marks C-terminal amidation, present on sermorelin (Arg29-NH2), where the dataset notes amidation is required for receptor potency. "cyclo[...]" denotes a ring closure: bremelanotide is written Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, a lactam bridge between the Asp and Lys side chains. Prefixes like D-Ala or D-Phe denote D-stereochemistry amino acids, which as a general principle resist proteolysis better than their L-forms; GHRP-2's sequence stacks several (D-Ala, D-2-Nal, D-Phe). Non-coded residues appear as abbreviations such as Aib (alpha-aminoisobutyric acid) in semaglutide and retatrutide, or Nle (norleucine). These symbols are the working shorthand of peptide chemistry, independent of any single molecule.

Section 04

Receptor and chemistry acronyms you will meet constantly

Beyond names, peptide records lean on a stable set of acronyms.

Beyond names, peptide records lean on a stable set of acronyms. On the receptor side, GPCR (G-protein-coupled receptor) is the broad family; many of these peptides act on class B GPCRs. The dataset's GHRH analogs (sermorelin, tesamorelin, both CJC-1295 forms) target GHRHR and couple through Gs to adenylyl cyclase, raising cAMP and engaging PKA, often phosphorylating the transcription factor CREB. GHS-R1a is the ghrelin/growth hormone secretagogue receptor that GHRP-2 agonizes, coupling instead through Gq/11 to phospholipase C. Incretin-class entries cite GLP-1R (semaglutide), and GIPR/GLP-1R/GCGR together for the triple agonist retatrutide. On the chemistry side, CAS (Chemical Abstracts Service Registry Number) and PubChem CID are unique compound identifiers; MW is molecular weight and the molecular formula sits beside it. DPP-IV (dipeptidyl peptidase-IV, also DPP-4) is the protease whose cleavage many of these analogs are engineered to resist. MDP (mitochondrial-derived peptide) classifies MOTS-c, encoded within the mitochondrial 12S rRNA region. AMPK, VEGFR2, NF-kB, and TrkB appear as named signaling nodes in specific mechanism summaries.

Section 05

Glossary of dataset peptides by naming logic

Grouping the dataset by how each name is built clarifies the families.

Grouping the dataset by how each name is built clarifies the families. Hormone-fragment names: sermorelin (GHRH 1-29), tesamorelin (GHRH 1-44, N-terminally lipid-modified), KPV (alpha-MSH 11-13), Semax (ACTH(4-7) plus Pro-Gly-Pro), TB-500 (thymosin beta-4 residues 17-23). Substituted-analog with strategy suffix: CJC-1295 without DAC (Mod GRF 1-29) and CJC-1295 with DAC, distinguished solely by the albumin-binding extension. Secretagogue series codes: GHRP-2, a synthetic hexapeptide GHS-R1a agonist also known as pralmorelin. Incretin -tide generics: semaglutide (GLP-1R agonist) and retatrutide (GIPR/GLP-1R/GCGR triple agonist), both fatty-diacid acylated. Sequence-or-composition-derived names: BPC-157 (a pentadecapeptide partial sequence of a gastric juice protein), GHK-Cu (the Gly-His-Lys tripeptide named for its one-letter sequence, complexed with copper), Epitalon (AEDG tetrapeptide), MOTS-c (a mitochondrial-derived peptide), and bremelanotide (also coded PT-141), a cyclic alpha-MSH analog. Each label, read against its dataset fields, resolves to a precise molecular identity rather than a marketing tag.

Straight answers

Frequently asked questions

What is the difference between GRF and GHRH in peptide names?

They are synonyms. GRF (growth hormone-releasing factor) and GHRH (growth hormone-releasing hormone) both name the same parent hormone, whose analogs target the GHRH receptor (GHRHR), a class B Gs-coupled GPCR. A label like GRF(1-29) and GHRH(1-29) describe the same 29-residue backbone; the choice of abbreviation is historical.

What does DAC stand for, and how do the two CJC-1295 entries differ?

DAC stands for Drug Affinity Complex, an albumin-binding strategy. In the dataset, CJC-1295 without DAC (Mod GRF 1-29) is a substituted GHRH(1-29) amide carrying D-Ala2, Gln8, Ala15, and Leu27. CJC-1295 with DAC adds a C-terminal Lys30 with an N-epsilon-maleimidopropionyl linker that forms a covalent thioether to cysteine-34 of serum albumin. They are two distinct molecules.

Why does the same peptide have several different names?

Different naming systems coexist. A laboratory assigns a development code (retatrutide was LY3437943; tesamorelin was TH9507), regulators or standards bodies assign a generic name with a class stem, and chemists describe it by parent-hormone fragment or sequence. Bremelanotide, for example, is also catalogued under the code PT-141.

What do prefixes like Ac-, D-, and the suffix -NH2 mean in a sequence?

Ac- marks N-terminal acetylation (seen in TB-500's Ac-LKKTETQ). A D- prefix marks a D-stereochemistry amino acid, which as a general chemistry principle tends to resist proteolytic cleavage. The -NH2 suffix marks C-terminal amidation; the dataset notes sermorelin's Arg29-NH2 amidation is required for receptor potency.

What is a mitochondrial-derived peptide (MDP)?

An MDP is a bioactive microprotein encoded within mitochondrial DNA rather than the nuclear genome. In the dataset, MOTS-c is classified as an MDP: a 16-residue peptide encoded by a short open reading frame within the mitochondrial 12S rRNA (MT-RNR1) region. Its mechanism summary describes AMPK-related signaling in cell-culture and rodent tissue models.

What do CAS Number and PubChem CID identify?

Both are unique compound identifiers used to pin down a molecule unambiguously. A CAS Registry Number is assigned by the Chemical Abstracts Service; a PubChem CID is PubChem's compound identifier. Catalogue entries pair these with the molecular formula and molecular weight (MW) so a named peptide maps to one defined chemical structure.

Why are so many of these peptides described as DPP-IV resistant?

DPP-IV (dipeptidyl peptidase-IV, also written DPP-4) is a protease that cleaves many native peptides near the N-terminus. Several dataset entries note engineered substitutions that resist this cleavage in vitro: the D-Ala2 substitution in the CJC-1295 backbone and the Aib8 substitution in semaglutide are recorded examples of stabilizing modifications studied in peptidase assays.

Keep exploring

Continue learning

Topic guideWhat Are Research Peptides?Research peptides are short chains of amino acids studied in the laboratory to understand how cells receive, interpret, and relay molecular signals. Because peptides sit at the size boundary between simple amino acids and large folded proteins, they make precise tools for asking narrow biochemical questions: which receptor does a given sequence engage, what second messenger rises inside the cell, and how does a small change to the chain alter that behavior? This reference looks at what defines a peptide, how peptides differ from proteins, what the label "research use only" (RUO) means, and why these molecules are examined in cell-based and cell-free systems rather than treated as finished products. Throughout, the framing is strictly in-vitro and receptor-signaling: the discussion concerns binding assays, cultured cells, isolated tissues, and structure-activity studies. Specific peptide facts cited here are drawn from a curated reference dataset of characterized research peptides. General principles of peptide chemistry are presented as established background. Nothing here describes administration, outcomes, or use in people; the goal is conceptual literacy for laboratory and educational contexts.Read →Topic guidePeptide Classes ExplainedPeptides are short chains of amino acids, and in laboratory research they are rarely studied as an undifferentiated group. Investigators sort them by what they do at the molecular level: which receptor they bind, which intracellular cascade they trigger, or which biochemical process they modulate in a cell-free or cultured-cell system. This reference organizes a set of research peptides by functional class rather than by chemical size or origin. The groupings used here are growth hormone secretagogues, incretin-receptor agonists, regenerative and matrix-signaling peptides, nootropic neuropeptides, cosmetic matricellular peptides, and mitochondrial-derived peptides. Each class is defined by a shared mechanistic signature observed in receptor-binding assays, second-messenger readouts, or gene-expression profiling. Every peptide-specific statement below is drawn from a curated dataset of in-vitro and structural findings, and the framing is strictly that of laboratory research: receptor occupancy, signal transduction, and biochemical activity. No human dosing, clinical outcome, or disease-treatment interpretation is offered. The goal is a clear conceptual map of how research peptides differ in molecular target and signaling logic.Read →Topic guideGrowth Hormone Secretagogues ExplainedGrowth hormone secretagogues (GHS) are a research category defined by mechanism rather than chemistry: each is a molecule that, in laboratory and cell-based systems, prompts pituitary somatotroph cells to release stored growth hormone instead of supplying growth hormone from outside the system. The category splits cleanly into two receptor branches. One branch acts at the growth hormone-releasing hormone receptor (GHRH-R); the other acts at the growth hormone secretagogue receptor type 1a (GHS-R1a), the receptor for endogenous ghrelin. These two receptors sit on the same cells but run through different G-protein cascades, which is why the distinction matters at the bench. This reference article explains GHS-R1a signaling, contrasts GHRH analogs with ghrelin-mimetic growth hormone-releasing peptides (GHRPs), describes why GH release is pulsatile, and clarifies the conceptual line between a secretagogue and an exogenous hormone. All statements here are framed strictly around in-vitro and receptor-signaling observations in research models. Peptide-specific facts are drawn only from a controlled reference dataset; broader statements are presented as general principles of peptide endocrinology, not as claims about any outcome.Read →Topic guideGHRH Analogs vs GHRPsTwo families of research peptides frequently appear together in growth-hormone-axis signaling studies: growth-hormone-releasing hormone (GHRH) analogs and growth-hormone-releasing peptides (GHRPs). Although both are described in the literature as growth hormone secretagogues, they engage entirely different cell-surface receptors and trigger different intracellular second-messenger cascades in laboratory models. GHRH analogs such as sermorelin and CJC-1295 act at the GHRH receptor (GHRHR), a class B Gs-coupled G-protein-coupled receptor on pituitary somatotroph cells. GHRPs such as GHRP-2 act at the growth hormone secretagogue receptor type 1a (GHS-R1a) - the ghrelin receptor - a class A GPCR coupled to a separate signaling arm. This article compares the two receptor systems as characterized in in-vitro and ex-vivo work, explains why their pathways are described as complementary, and grounds each peptide-specific claim in the reference dataset. The framing throughout is strictly receptor-signaling and laboratory-research: cAMP and calcium readouts in cultured cells, binding constants, and structure-activity relationships, not clinical outcomes. Understanding the receptor-level distinction clarifies why these two peptide classes are studied as separate but convergent inputs onto the somatotroph.Read →

For in-vitro laboratory research use only. Not for human or animal consumption. Educational content, not medical advice; not intended to diagnose, treat, cure, or prevent any disease. Not evaluated by the FDA.